Curated News
By: NewsRamp Editorial Staff
August 03, 2026
NeuroOne to Report Q3 FY2026 Financial Results on August 13
TLDR
- NeuroOne (NMTC) will release Q3 FY2026 results on Aug 13, offering investors a chance to gauge its financial health.
- NeuroOne will host an earnings call on August 13, 2026, at 8:30 a.m. ET, with dial-in and webcast options, followed by a replay until August 27.
- NeuroOne's electrode technology aims to improve outcomes for neurological disorder patients, potentially reducing surgeries and costs.
- NeuroOne's platform includes FDA-cleared products for brain and trigeminal nerve ablation, with R&D in spinal cord stimulation.
Impact - Why it Matters
This news matters because NeuroOne's upcoming financial results will provide key insights into the company's performance and progress in the neurological medical device market. For investors and healthcare professionals, the earnings call offers a chance to gauge the adoption of its FDA-cleared electrode and ablation systems, which have the potential to improve surgical outcomes and reduce healthcare costs. The company's ongoing R&D in areas like drug delivery and spinal cord stimulation could signal future growth opportunities, making this announcement relevant for those tracking innovation in neurological treatments.
Summary
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on transforming the surgical diagnosis and treatment of neurological disorders, has announced it will release its fiscal third quarter 2026 financial results before market open on Thursday, August 13, 2026. The company will hold an investor conference call and webcast at 8:30 a.m. Eastern time on the same day to discuss the results, provide a corporate update, and answer questions from participants. The call details include a U.S. toll-free dial-in number (888-506-0062), an international dial-in (973-528-0011), and participant access code 549778. A live webcast will be available via the provided link, and a replay will be accessible through August 27, 2026, with a webcast replay available through August 13, 2027.
NeuroOne markets a minimally invasive, high-definition electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These products aim to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering both diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. For more information, visit the company's website at nmtc1.com. The original press release was distributed via NEWMEDIAWIRE, and the full release can be viewed on www.newmediawire.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroOne to Report Q3 FY2026 Financial Results on August 13
